There have been remarkable advances in the targeted treatment of advanced non-small cell
lung cancer (NSCLC) over the past several years. Survival outcomes are steadily improving …

Importance of the field: Lung cancer is the most common cancer in the world today, in terms
of both incidence and mortality. Non-small-cell lung cancer (NSCLC) accounts for about …

The last decade has witnessed the development of oncogene-directed targeted therapies
that have significantly changed the treatment of non-small-cell lung cancer (NSCLC). In this …

Lung cancer remains the leading cause of malignancy-related mortality worldwide, with over
one million cases diagnosed yearly. Non-small-cell lung cancer (NSCLC) accounts for> …

Clinical trial data continue to emerge on treatments in advanced non-small cell lung cancer
(NSCLC), supporting the strategy that histology and molecular driver mutations should guide …

Lung cancer remains the leading cause of cancer related death worldwide. Despite broad
advances in diagnostics and therapy, the five-year overall survival for patients with …

Lung cancer is the most common cause of cancer-related death worldwide, owing to its
metastatic spread at the time of diagnosis. As a result, chemotherapy is the standard of care …

Conventional therapy for non-small cell lung cancer (NSCLC) has reached a plateau in
increasing patient survival and overall prognosis still remains dismal. Advances in the …

N on-small cell lung cancer (NSCLC) is the leading cause of cancer mortality worldwide,
although evidence now suggests that novel biological agents could improve survival of …

Targeted therapies focus on signaling pathways in cancer cells and other molecular
processes involved in oncogenesis. Recent approaches affect the following major groups …